home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

23.83 +0.68 (+2.94%)

Official Closing Price Updated: 4:15 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

33 34 Next >

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? ↗

January 25, 2024

It's always tough to be compared to a giant.

Via The Motley Fool

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

January 23, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Via MarketBeat

Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today ↗

January 22, 2024

One pundit feels there is solid potential in one of the company's more recently approved drugs.

Via The Motley Fool

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗

January 16, 2024

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Via InvestorPlace

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

January 16, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics ↗

January 10, 2024

Via Benzinga

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session

January 09, 2024

Via Investor Brand Network

Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday? ↗

January 09, 2024

Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...

Via Benzinga

Topics Economy

Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year ↗

January 09, 2024

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product

Via Benzinga

Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match ↗

January 09, 2024

Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.

Via InvestorPlace

Why Is Sarepta Therapeutics (SRPT) Stock Up Today? ↗

January 09, 2024

Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.

Via InvestorPlace

The Latest Analyst Ratings for Sarepta Therapeutics ↗

December 12, 2023

Via Benzinga

Could Sarepta Therapeutics Stock Help You Become a Millionaire? ↗

December 09, 2023

Can this struggling stock turn its fortunes around?

Via The Motley Fool

Analyst Ratings for Sarepta Therapeutics ↗

November 21, 2023

Via Benzinga

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday ↗

January 09, 2024

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

Via Benzinga

Topics Stocks

2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗

January 09, 2024

Last year wasn't great for either stock, but that's no reason to ignore them.

Via The Motley Fool

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

January 08, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 29, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

3 Things About Sarepta Therapeutics Every Smart Investor Knows ↗

December 28, 2023

Mastering this stock requires appreciating a few scientific nuances.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

December 27, 2023

Via Benzinga

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

December 22, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond ↗

December 17, 2023

Many investors are bailing out, but that might be a mistake.

Via The Motley Fool

My Take: 4 Strong Growth Stocks to Buy This Week ↗

December 08, 2023

These strong stocks are still available at a great price. That may not be the case a whole lot longer.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

November 18, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com